PMPankaj Musyuni

Pankaj Musyuni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pankaj Musyuni has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • An overview of regulatory perspectives of nanoparticles and liposomal products in India and USA

    by Rinshu Dabas, Pankaj Musyuni, Geeta Aggarwal

    Nanoparticles and Liposomal products have significantly contributed for managing various disorders and diseases. Drug delivery system is important and assisting in developing various therapeutic regimen. The present write-up discussed the role of novel drug delivery system, particularly applications of nanoparticles and liposomal products and regulatory requirement for these products. The article emphasises that there are enormous research opportunities and global collaboration is essential for promoting research and drug approval.


  • Regulatory perspective of cancer drug development: An overview

    by Anurag Panchal, Pankaj Musyuni, Geeta Aggarwal

    Despite the fact postulated that better technology and scientific knowledge will lead to better medical services, the truth is very distinctive. Despite having the most cutting-edge scientific knowledge, America and the majority of Europe ironically have the maximum cancer rates. It shows that using technology and science alone to treat cancer and other diseases is inadequate. Additionally, it is now widely acknowledged that majority of pre-clinical tumour models are insufficient, because more than 95% of substances and molecules that kill cancerous cells in culture or reduce tumours in animals may fail in clinical studies in people. Additionally, the majority of anti-cancer medications which are authorised by regulatory bodies like the FDA have either no impact on survival of cancer patients or may raise by a few months. This is amidst the fact that majority of presently offered chemotherapeutic drugs are very expensive, leading to a lack of affordability.


  • Open Access

    A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy

    by Pankaj Kumar, Bharti Mangla, Shamama Javed, Waquar Ahsan, Pankaj Musyuni, Durgaramani Sivadasan, Saad S. Alqahtani, Geeta Aggarwal

    Breast cancer being one of the most frequent cancers in women accounts for almost a quarter of all cancer cases. Early and late-stage breast cancer outcomes have improved dramatically, with considerable gains in overall survival rate and disease-free state. However, the current therapy of breast cancer suffers from drug resistance leading to relapse and recurrence of the disease. Also, the currently used synthetic and natural agents have bioavailability issues which limit their use. Recently, nanocarriers-assisted delivery of synthetic and natural anticancer drugs has been introduced to the breast cancer therapy which alienates the limitations associated with the current therapy to a great extent. Significant progress has lately been made in the realm of nanotechnology, which proved to be vital in the fight against drug resistance. Nanotechnology has been successfully applied in the effective and improved therapy of different forms of breast cancer including invasive, non-invasive as well as triple negative breast cancer (TNBC), etc. This review presents a comprehensive overview of various nanoformulations prepared for the improved delivery of synthetic and natural anticancer drugs alone or in combination showing better efficacy and pharmacokinetics. In addition to this, various ongoing and completed clinical studies and patents granted on nanotechnology-based breast cancer drug delivery are also reviewed.


  • An overview of regulation for nutraceuticals and concept of personalized nutraceuticals

    by Saurav Tomar, Pankaj Musyuni, Geeta Aggarwal

    Nutraceuticals are essentially nutritional components that have a vital role in developing and maintaining the body’s regular functions, which keeps people healthy. The nutraceutical sector is also primarily driven by the existing global population and trends. Examples of foods considered as nutraceuticals include prebiotics, fibre, polyunsaturated fatty acids, probiotics, antioxidants, and other natural or herbal foods. Some of the most serious health problems of the 20th century, like COVID-19 and diabetes mellitus, are managed with the help of the preceding nutraceuticals. As we move into a time of health and medicine, the food industry as a whole has become more focused on research.


  • A retrospective analysis on the product recall due to solvent and mineral residue issues

    by Salman Ahmed, Pankaj Musyuni, Geeta Aggarwal

    Drug recalls are essential to maintaining the safety process because the medical industry’s top objective is primarily to deliver higher-quality goods to a larger population. They do this by eliminating subpar products from the market. Drug recalls are increasing quickly as a result of increased investigation rates, the emergence of industrialization and the online era into the sector, and regulatory authorities and health experts are now focusing on more stringent regulations to prevent further recalls of faulty pharmaceutical drugs. The purpose of the present write-up is to give an overview of how drug recalls work with the help pf examples of recalls due to presence of undesired solvents and mineral residue, how they affect the pharmaceutical business, and what can be done to stop them.


  • Application of Nutraceuticals in Managing Osteoarthritis and Osteoporosis

    by Pankaj Musyuni, Deepak Kumar, Deepti Pandita, Gaurav Kumar Jain, Manju Nagpal, Geeta Aggarwal

    Background: Several health problems, especially musculoskeletal disorders, are caused by differences in work cultures and human lifestyles around the world. While the conventional approach to treating such conditions emphasizes a balanced work-life and daily exercise, nutraceuticals have proven to be successful. Nutraceuticals are dietary compounds that help sustain cartilage metabolism homeostasis, reducing articular pain. Dietary intake of a variety of nutraceuticals is thought to be essential for controlling and, more specifically, preventing osteoarthritis and osteoporosis. Objective: The current article offers a succinct overview in which data was gathered and searched using specific key terms related to nutraceuticals, osteoarthritis, and osteoporosis that were available in public domains for analysis and evaluation. Method: The current write-up offers a concise summary of disease and its relevance as to how nutraceuticals are helpful, based on the defined findings and their interpretation. The present review also discusses the existing literature, patents, and current studies in the era of nutraceuticals for osteoarthritis and osteoporosis treatment, offering a rational basis for further investigation and research. Result: This article discusses a wide variety of nutraceuticals with possible uses for osteoarthritis and osteoporosis patients. An analysis revealed that nutraceuticals' efficacy has been established. However, further study and investigation are needed to determine their protection. Conclusion: As a result of this analysis, it was concluded that more innovation and technology transfer were required. It was also concluded that greater industry-academic collaboration was required to begin more effective research in the treatment of osteoarthritis and osteoporosis with nutraceuticals.


  • A review and analysis of product recall for pharmaceutical drug product

    by Ashish Miglani, Chandan Saini, Pankaj Musyuni, Geeta Aggarwal

    The pharmaceutical industry's primary concern is to provide high-quality drug products to the general public, so drug recalls play an important role in maintaining the quality system by removing defective products from the market. Pharmaceutical product recalls are increasing at an alarming rate as a result of increased inspection rates and the introduction of modernization and the digital world into the industry, raising concerns for regulatory agencies and public health to focus on more stringent regulations to control future recalls of defective drug products. This article will provide an overview of recall procedures, their impact on the pharmaceutical industry, and the various steps taken to reduce pharmaceutical recalls.


  • Review of form 483s and warning letters to pharmaceutical manufacturers issued by USFDA

    by Chandan Saini, Ashish Miglani, Pankaj Musyuni, Geeta Aggarwal

    Regular inspections are carried out to ensure system conformity by the Food and Drugs Regulatory Authority (FDA) of the United States one of the most stringent regulatory authorities in the world. The inspectors send Form 483 to the management after the inspection, detailing the inappropriate conditions. Because the FDA guidelines are difficult to comply with, a company can contravene the regulations. If any significant infringements can affect the protection, quality, effectiveness, or public health of the drug is identified, the FDA issues advice to the company. Warning Letters (WL) shall be an official notification of non-compliance with federal law within a period to be issued by manufacturer, clinician, distributor, or responsible person in the company. The delivery of a letter has a considerable impact on the company's reputation and position in the market. Inadequate WL reactions could lead to a refusal, import denial, memorandum or even conviction and order. A brief study was conducted in this document of Form 483 and WL for four years (2017–2020) on an understanding the regulatory provisions.